FATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT
Taurunum Medical Journal · 31.05.2026 · 40 (1)
DOI: 10.63696/tmj202601005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Taurunum Medical Journal, online erschienen am 31.05.2026. Verfasst von Bojan Mitrovic und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
<p><strong>Introduction</strong><strong>.</strong> Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease nowadays which has contributed to significant cardiovascular and hepatic morbidity and mortality. Recognizing the metabolic concept resulted in an evolution in disease nomenclature, as well as the development of innovative treatments for MASLD, the hepatic manifestation of metabolic syndrome.</p> <p><strong>Objective</strong><strong>.</strong> To present contemporary trends in the management of MASLD.</p> <p><strong>Methods</strong><strong>.</strong> For the search methodology, we used the PubMed database. We employed the following keywords to search for original articles, reviews, and clinical guidelines from 2018. to 2025. year, such as „NAFLD/MASLD“, „NAFLD/MASLD biomarkers“, „NAFLD/MASLD diagnostic scores“, „NAFLD/MASLD innovative therapy“. We used original articles and reviews written in English, Serbian and Balkan-familiar languages. Special attention was given to the FIB-4 algorithm, newly developed non-invasive scores (SAFE, LiverRisk, MAFS), and biomarkers (MDA, 8-OHdG, CK-18, PRO-C3).</p> <p><strong>Results</strong><strong>.</strong> MASLD has been associated to an increased risk of liver fibrosis and cirrhosis, hepatocellular carcinoma (HCC), and cardiovascular diseases. Emerging biomarkers enable early and accurate diagnosis and monitoring of treatment response, while innovative treatments including PPAR agonists, GLP-1 receptor agonists, and Resmetirom are mapping the personalized MASLD treatment.</p> <p><strong>Conclusion</strong><strong>.</strong> MASLD is a chronic systemic disease requiring a multidisciplinary approach. Proper diagnosis and personalized innovative therapy create the favorable conditions for reducing cardiovascular and hepatic morbidity and mortality.</p>
Zitieren
APA
Mitrovic, B., Tomašević, R., & Gluvić, Z. (2026). FATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT. Taurunum Medical Journal, 40(1). https://doi.org/10.63696/tmj202601005
Vancouver
Mitrovic B, Tomašević R, Gluvić Z. FATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT. Taurunum Medical Journal. 2026;40(1). doi:10.63696/tmj202601005
BibTeX
@article{Mitrovic2026,
author = {Mitrovic, Bojan and Tomašević, Ratko and Gluvić, Zoran},
title = {FATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT},
journal = {Taurunum Medical Journal},
year = {2026},
volume = {40},
number = {1},
doi = {10.63696/tmj202601005}
}
EUVIMED